Payment overview · 2025
General Payments
$133.38
1 reported records · 1 companies
Healthcare provider profile · identity verified
James C Yang, MD, MPH
Allopathic & Osteopathic Physicians|Internal Medicine · WASHINGTON, DC · NPI 1831355486
Verified facts
What the public records show
CMS Open Payments records show James C Yang, MD, MPH received $133.38 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $133.38 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $133.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 593 | 211 |
| Lisinopril | Lisinopril | 324 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 300 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 271 | 106 |
| Losartan Potassium | Losartan Potassium | 248 | 97 |
| Gabapentin | Gabapentin | 239 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 199 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 193 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 187 | 59 |
| Duloxetine Hcl | Duloxetine Hcl | 185 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 173 | 58 |
| Omeprazole | Omeprazole | 152 | 64 |
| Trazodone Hcl | Trazodone Hcl | 151 | 58 |
| Famotidine | Famotidine | 150 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 140 | 87 |
| Metformin Hcl | Metformin Hcl | 138 | 49 |
| Furosemide | Furosemide | 136 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 42 |
| Bupropion Xl | Bupropion Hcl | 110 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 39 |
| Ibuprofen | Ibuprofen | 101 | 36 |
| Simvastatin | Simvastatin | 100 | 34 |
| Alendronate Sodium | Alendronate Sodium | 93 | 35 |
| Atenolol | Atenolol | 91 | 36 |
| Metformin Hcl Er | Metformin Hcl | 86 | 35 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 82 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 27 |
| Carvedilol | Carvedilol | 75 | 24 |
| Sertraline Hcl | Sertraline Hcl | 72 | 31 |
| Glipizide | Glipizide | 69 | 30 |
| Jardiance | Empagliflozin | 64 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 21 |
| Pradaxa | Dabigatran Etexilate Mesylate | 55 | 21 |
| Allopurinol | Allopurinol | 54 | 22 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 54 | 41 |
| Ozempic | Semaglutide | 54 | 16 |
| Finasteride | Finasteride | 53 | 19 |
| Spironolactone | Spironolactone | 50 | 19 |
| Warfarin Sodium | Warfarin Sodium | 50 | 18 |
| Naproxen | Naproxen | 49 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 13 |
| Potassium Chloride | Potassium Chloride | 44 | 15 |
| Cephalexin | Cephalexin | 43 | 34 |
| Lovastatin | Lovastatin | 43 | 16 |
| Naltrexone Hcl | Naltrexone Hcl | 43 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 17 |
| Lorazepam | Lorazepam | 41 | 13 |
| Tramadol Hcl | Tramadol Hcl | 40 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | 11 |
| Prednisone | Prednisone | 39 | 29 |
| Meloxicam | Meloxicam | 38 | 13 |
| Montelukast Sodium | Montelukast Sodium | 38 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 38 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 37 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 12 |
| Alvesco | Ciclesonide | 35 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 31 | suppressed |
| Eliquis | Apixaban | 31 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | 13 |
| Enoxaparin Sodium | Enoxaparin Sodium | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 11 |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | 15 |
| Varenicline Tartrate | Varenicline Tartrate | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 19 |
| Breyna | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 21 | 12 |
| Topiramate | Topiramate | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Azithromycin | Azithromycin | 19 | 17 |
| Fluocinonide | Fluocinonide | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 11 |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Flunisolide | Flunisolide | 12 | suppressed |
| Fluorouracil | Fluorouracil | 12 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Motegrity | Prucalopride Succinate | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $133.38 · 1 records | ABBVIE INC. | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error